Abstract: The present invention is related to a recombinant nucleic acid construct comprising in 5?-> 3? direction a 5? UTR, a coding region coding for an effector molecule, and a 3? UTR, wherein the 5? UTR is selected from the group consisting of a 5? UTR of a gene coding for MCP-1 or a derivative thereof having a nucleotide identity of at least 85%, a 5? UTR of a gene coding for RPL12s.c. or a derivative thereof having a nucleotide identity of at least 85%, a 5? UTR of a gene coding for Ang-2 or a derivative thereof having a nucleotide identity of at least 85%, a 5? UTR of a gene coding for HSP70 or a derivative thereof having a nucleotide identity of at least 85%, a 5? UTR of a gene coding for H3.3.

Abstract: The present invention is related to a composition comprising a lipid composition, a tricarboxylic acid and a nucleic acid molecule, wherein the lipid composition comprises a cationic lipid, a neutral lipid and a shielding lipid, wherein a positive charge excess arising from a larger number of positive charges provided by the cationic lipid molecules in the composition compared to the smaller number of negative charges provided by the nucleic acid molecules in the composition is compensated by the charges provided by the tricarboxylic acid; and methods of use of such composition.

Abstract: The present invention discloses modified guide RNAs which can be used with the CRISPR CAS 9 system for modifying gene expression, particularly in mammalian cells for medical or research uses.